



Representative Legal Matters

Oren Livne

- RayzeBio (a Bristol Myers Squibb Company) in its Research Collaboration and License Agreement with Ratio Therapeutics to advance a novel radiopharmaceutical program.
- Bayer in its acquisition of Perfuse Therapeutics for up to USD 2.45 billion including USD 300 million upfront and additional development, regulatory and commercial milestone payments based on success criteria.
- Innovative Molecules on its strategic partnership with Alfasigma covering the parenteral formulation of adibelvir for the treatment of herpes simplex virus encephalitis, including payments of up to EUR 125 million in upfront and milestone payments.
- icometrix, a Belgian-based leader in AI-powered medical imaging, in its sale to GE Healthcare.
- Bristol Myers Squibb on the transfer of Juno Therapeutics GmbH to TQ Therapeutics GmbH.
- Galapagos in the planned creation of a new company with approximately EUR 2.45 billion in cash dedicated to building a pipeline of innovative medicines through transformational transactions and amendment of its 10-year global Option, License and Collaboration Agreement with Gilead.
- L'Oréal in its partnership with NanoEntek related to technology used in L'Oréal Cell BioPrint, a tabletop hardware device that provides personalized skin analysis.
- Bristol Myers Squibb in its research collaboration and option agreement with AI Proteins for miniprotein- based therapeutics valued up to USD 400 million.
- Astellas in its exclusive option and license agreement with AviadoBio for an investigational gene therapy targeting frontotemporal dementia, including a USD 20 million equity investment and up to USD 30 million in option exercise payments, plus the potential for USD 2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option.
- Astellas in its exclusive option and license agreement with AviadoBio for an investigational gene therapy targeting frontotemporal dementia, including a USD 20 million equity investment and up to USD 30 million in option exercise payments, plus the potential for USD 2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option.
- Astellas in its exclusive option and license agreement with AviadoBio for an investigational gene therapy targeting frontotemporal dementia, including a USD 20 million equity investment and up to USD 30 million in option exercise payments, plus the potential for USD 2.18 billion in license fees and milestone payments plus royalties if Astellas exercises its option.
- Abbott in its global partnership to connect its continuous glucose monitoring system with Medtronic's insulin delivery devices.



- Astellas in its Research Collaboration and License Agreement with Elpiscience for novel bispecific macrophage engagers, including up to USD 37 million in upfront and option fees and potentially more than USD 1.7 billion in future development, regulatory, and commercial milestones.
- Galapagos on the intended transfer of its Jyseleca® business to Alfasigma, including the European and UK Marketing Authorizations, the commercial, medical and development activities for Jyseleca® and approximately 400 FTEs in 14 European countries.
- Astellas in its strategic collaboration and option agreement with Cullgen to advance innovative targeted protein degraders, with compensation potentially exceeding USD 1.9 billion if Astellas exercises all of its license options and all milestones for all programs are achieved.
- L'Oréal in its strategic partnership with Debut to develop a wide variety of novel ingredients and beauty and personal care products using Debut's proprietary cell-free and biotechnology model.
- L'Oréal in its collaboration with Verily to incorporate Verily's stabilization technology into L'Oréal's smart makeup applicator for users with limited hand and arm mobility.
- Merck Sharp & Dohme in its collaboration and license agreement with PeptiDream Inc. for the discovery and development of novel peptide drug candidates, including the potential for up to USD 2.1 billion in regulatory, development and commercial milestones.
- Vividion Therapeutics (a wholly owned and independently operated subsidiary of Bayer AG) in its strategic collaboration with Tavros Therapeutics to discover and enhance targeted oncology programs, including an upfront of USD 17.5 million, up to USD 430.5 million in milestone payments for four initial programs, and, if Vividion exercises its option for up to five more targets, up to USD 482 million in additional payments.
- Bristol Myers Squibb in its research collaboration with SyntheX to discover and develop targeted protein degradation therapeutics, under which SyntheX will receive an upfront and is eligible for up to USD 550 million in performance-based milestone payments, as well as royalties on global net sales.
- Astellas in its worldwide strategic collaboration with Sutro Biopharma to advance novel immunostimulatory antibody-drug conjugates (iADCs) under which Sutro will receive an upfront cash payment of USD 90 million and may be eligible to receive up to USD 422.5 million in milestones for each product candidate plus tiered royalties.
- Galapagos in its acquisition of Cellpoint (including its decentralized point-of-care manufacturing model for CAR-T therapy) for an upfront amount of EUR 125 million, with milestone payments up to EUR 100 million.
- Bristol Myers Squibb in its strategic collaboration with Amphista Therapeutics for discovery and development of targeted protein degradation therapeutics, including an upfront payment of USD 30 million, the potential for up to USD 1.25 billion in milestone and other payments, as well as royalties on global net sales of product.



- Abbott in its partnership with CamDiab and Ypsomed for a new automated insulin delivery system for people living with diabetes.
- L'Oréal in its strategic partnership with Verily to advance precision skin health.
- Astellas in its strategic research collaboration with FIMECS to discover protein degraders against multiple targets.
- Merck Sharp & Dohme in its collaboration and option agreement with ONSSI.
- Bayer in its acquisition of drug discovery company Vividion Therapeutics for USD 1.5 billion upfront and up to USD 500 million in success-based milestone payments.
- Astellas in its license agreement with ExCellThera for the in vitro use of certain molecules in the field of pluripotent stem cells (PSCs) and PSC-derived cells.
- MIMETAS in its collaboration with Roche to develop human disease models for drug development.
- CytoSorbents in its global co-marketing agreement with B. Braun to promote the OMNI® continuous blood purification platform with CytoSorb®.
- MyoKardia, a wholly-owned subsidiary of Bristol Myers Squibb, in its research collaboration with Avidity Biosciences to demonstrate the potential utility of AOCs in cardiac tissue.
- argenx in its strategic collaboration for efgartigimod in greater China, including USD 75 million in upfront Zai Lab equity and USD 100 million in near-term milestone and other payments.
- Abbott in its agreement with eMed for the delivery and administration of Abbott's BinaxNOW™ COVID-19 test for virtually guided at-home use.
- Galapagos in its new commercialization and development agreement with Gilead for Jyseleca® (filgotinib) under which Galapagos assumes sole responsibility for Europe
- Abbott in its collaboration with Supersapiens to advance Abbott's Libre Sense Glucose Sport Biosensor, which is designed to help athletes better understand the correlation between their glucose levels and their athletic performance.
- BeiGene in its exclusive license agreement with Singlomics (Beijing DanXu) Biopharmaceuticals to develop, manufacture and commercialize Singlomics' investigational anti-COVID-19 antibodies globally outside of greater China.
- CytoSorbents in its collaboration with Terumo Cardiovascular to commercialize CytoSorb® in ten US hotspot states under the FDA's Emergency Use Authorization for COVID-19.
- CytoSorbents in its agreements with InvoSurg and Surgical Partners to commercialize CytoSorb® in the U.S. Northeast, Mid-Atlantic, and Florida under the FDA's Emergency Use Authorization for COVID-19.

- Abbott in its agreement with Tandem Diabetes Care to develop and commercialize integrated diabetes solutions that combine Abbott's FreeStyle Libre continuous glucose monitoring technology with Tandem's insulin delivery products to provide options to simplify and tailor diabetes management.
- GSK Consumer Healthcare in its collaboration with Mammoth Biosciences to develop a rapid, handheld CRISPR-based test to detect novel coronavirus infections.
- Galapagos in its collaboration with Ryvu Therapeutics focused on the discovery and development of novel small molecule drugs in inflammation.
- Abbott in its collaboration with Insulet to integrate next-generation glucose sensing and automated insulin delivery technologies.
- CytoSorbents in its agreement with China Medical System to bring CytoSorb® to mainland China to treat critically-ill patients with COVID-19 coronavirus infection.
- AbbVie in the expansion of its TriTAC discovery collaboration agreement with Harpoon.
- AbbVie in its exclusive license agreement with Disc Medicine granting worldwide rights to a series of hemojuvelin antagonist monoclonal antibodies.
- Abbott in its collaboration with Omada Health to offer an integrated digital health and coaching experience for people with type 2 diabetes.
- Mithra in its landmark license and supply agreement with Mayne Pharma for Estelle® in the United States, for license fees of at least USD 295 million and a 9.6% equity stake across two tranches.
- Galapagos in its transformative USD 5.1 billion research and development collaboration with Gilead.
- H. Lundbeck A/S in its acquisition of Abide Therapeutics, a clinical-stage biopharmaceutical company focusing on multiple indications in neurology and psychiatry, for USD 250 million upfront and up to an additional USD 150 million in development and sales milestones.

Prior to joining the Firm, Oren provided counsel to the following:

- Shire in its agreement with Mirum Pharmaceuticals pursuant to which Mirum has obtained exclusive global rights to develop and market maralixibat, an oral inhibitor of the apical 2 sodium dependent bile acid transporter, and Shire has received undisclosed financial consideration and an equity position in Mirum.
- Astellas in its global commercialization agreement with Seattle Genetics Inc. to commercialize enfortumab vedotin.
- Merck in its up to USD 5.76 billion strategic collaboration with Eisai Co. Ltd. for the worldwide co-development and co-commercialization of Eisai's Lenvima (lenvatinib mesylate).



- Celgene in its global immuno-oncology collaboration with BeiGene to advance PD-1 inhibitor program for solid tumor cancers.
- AbbVie in its strategic collaboration with Alector to develop and commercialize medicines for the treatment of Alzheimer's disease and other neurodegenerative disorders.
- Regeneron in its clinical collaboration with ISA Pharmaceuticals B.V., with ISA receiving an upfront payment and an equity investment in exchange for an option for an exclusive global license.
- Takeda in its collaboration with Ultragenyx to develop and commercialize therapies for rare genetic diseases.
- Incyte its global strategic collaboration with Merus for the research, discovery, development and commercialization of bispecific antibodies with a focus on immuno-oncology.
- Amarin in its collaboration agreement with Mochida Pharmaceutical for the development and commercialization of drug products based on the omega-3 acid, EPA, to treat patients at risk of cardiovascular disease.
- Radius Health its license and development agreement with Teijin relating to abaloparatide SC in Japan.
- SK Capital Partners in its acquisition of the Textile Chemicals, Paper Specialties, and Emulsions businesses of Clariant, representing approximately USD 1.3 billion in revenues from 25 facilities worldwide.
- Multiple clients in license, research, option, service, and other agreements with various universities including Rutgers University, Princeton University, the University of California, Johns Hopkins University, Purdue University, University of Maryland, Hebrew University, and University of South Florida.
- Incyte in the acquisition of Ariad's European operations and in-license of Iclusig® in Europe.
- Takeda in its collaboration agreement with Cardurion Pharmaceuticals.
- Celgene in its collaboration agreement with Prothena to develop new therapies for a broad range of neurodegenerative diseases.
- Shire in its worldwide development and commercialization collaboration with Parion Sciences to ENaC inhibitors for dry eye disease and other ophthalmic indications.
- Celgene in its drug-discovery collaboration with Cancer Research Technology, to discover, develop and commercialize new anti-cancer treatments centered on mRNA translation.
- SK Capital Partners its acquisition of D.B. Western Inc.-Texas, an owner and operator of a formaldehyde and formaldehyde derivatives plant located in Texas.



- BioClinica in its sale to JLL Partners, Inc. for USD 123 million in a going-private transaction.
- Large pharmaceutical company, in its sale of manufacturing plants in Colorado, Germany and France.